ADAM17 and hepatocellular carcinoma: identified a non-hydroxamate-based inhibitor, called thioxodihydro pyrimidindione ZLDI-8, which reversed taxol resistance, displayed an IC50 value equal to 6.85 μM against ADAM17 (259), and inhibited metastasis of hepatocellular carcinoma (271).